Human butyrylcholinesterase - Altimmune
Alternative Names: NEX 91; Protexia; rBChE; rBChE bioscavenger; Recombinant human butyrylcholinesteraseLatest Information Update: 18 Jun 2021
At a glance
- Originator PharmAthene
- Class Antidotes; Butyrates; Cholinesterases
- Mechanism of Action Scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Poisoning
Highest Development Phases
- No development reported Alzheimer's disease; Poisoning
Most Recent Events
- 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
- 04 May 2017 Altimmune merged with PharmAthene and the combined entity was renamed as Altimmune
- 08 Sep 2014 Human butyrylcholinesterase - PharmAthene is available for licensing as of 08 Sep 2014. http://www.pharmathene.com/